Annual Report & Financial Statements

The report describes Hemogenyx Pharmaceuticals' progression into clinical-stage development, including the FDA's lifting of the HG-CT-1 clinical hold in January 2024. It records advances across the CBR and CDX programs and a December 2024 Kure.ai collaboration to co-develop an HG-CT-1 manufacturing platform. The company raised £3,925,000 before expenses during 2024 while reporting no revenue and a £5,625,478 loss. ESG disclosure is limited but includes a TCFD progress table, Board oversight of climate matters, and a statement that UK energy use was below 40,000kWh.

Report type

Annual Report with Sustainability Disclosures

Class

Embedded

Scope

Full report

Fiscal year

2024

Period

Ends 31 December 2024

Language

English

Pages

 

File size

 

Restatement

Disclosed

GRI

••••••

SASB

••••••

TCFD

••••••

ISSB

••••••

ESRS

••••••

Integrated Reporting Framework

••••••

GHG Protocol

••••••

EU Taxonomy

••••••

CDP

••••••

Other

••••••

Assessment

••••••

Basis

••••••

Statement included

••••••